Summit Therapeutics Inc Ordinary Shares SMMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
-
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
-
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
-
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
-
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
-
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
-
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
-
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Trading Information
- Previous Close Price
- $15.83
- Day Range
- $15.13–15.70
- 52-Week Range
- $12.07–29.23
- Bid/Ask
- $15.38 / $15.62
- Shares Outstanding
- 797.75M
- Market Cap
- $12.41B
- Volume/Avg
- 4M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 265
- Website
- https://www.smmttx.com
Valuation
|
Metric
|
SMMT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 19.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SMMT
Financial Strength
|
Metric
|
SMMT
|
|---|---|
Quick Ratio | 6.67 |
Current Ratio | 6.96 |
Interest Coverage | — |
Quick Ratio
SMMT
Profitability
|
Metric
|
SMMT
|
|---|---|
Return on Assets (Normalized) | −86.16% |
Return on Equity (Normalized) | −103.14% |
Return on Invested Capital (Normalized) | −99.98% |
Return on Assets
SMMT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>^NSY$ | LOCK|$@&px | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Gj^Y@B | LOCK|gmvc | $84B | |||
| Moderna Inc
MRNA
| LOCK|?zYGjh | LOCK|ht | $81B | |||
| argenx SE ADR
ARGX
| LOCK|YVVhk@ | LOCK|ZGH | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H^@FPq | LOCK|WhB | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^w#?&rR | LOCK|pnV^> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%$PmM&! | LOCK|^<#r | $28B | |||
| Incyte Corp
INCY
| LOCK|#$^^LF | LOCK|tph | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|F%?jL! | LOCK|#c | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|YD#prhH | LOCK|&d | $14B |
United States